DOI: 10.1182/blood.2023021221 ISSN: 0006-4971
CAR T-Cell Therapy in Multiple Myeloma: Mission Accomplished?
Leo Rasche, Michael Hudecek, Hermann Einsele- Cell Biology
- Hematology
- Immunology
- Biochemistry
BCMA-CAR T-cells are the most potent treatment against multiple myeloma. Here, we review the increasing body of clinical and correlative pre-clinical data that support their inclusion into first-line therapy and sequencing prior to T-cell-engaging antibodies. The ambition to cure multiple myeloma with (BCMA-)CAR T-cells is informed by genomic and phenotypic analysis that assess BCMA expression for patient stratification and monitoring, steadily improving early diagnosis and management of side effects, and advances in rapid, scalable CAR T-cell manufacturing to improve access.